Enhancing safety: Multi-institutional FMEA and FTA on 177 Lu $^{177}{\rm Lu}$ -based radio-pharmaceutical therapy.

Autor: George SC; Department of Radiation Oncology, Miami Cancer Institute, Baptist Health, Miami, Florida, USA.; Department of Physics, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamil Nadu, India.; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA., Aguirre S; Department of Radiation Oncology, Miami Cancer Institute, Baptist Health, Miami, Florida, USA., Maughan NM; Department of Radiation Oncology, Intermountain Health, Provo, Utah, USA., Tolakanahalli R; Department of Radiation Oncology, Miami Cancer Institute, Baptist Health, Miami, Florida, USA.; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA., Samuel EJJ; Department of Physics, School of Advanced Sciences, Vellore Institute of Technology, Vellore, Tamil Nadu, India., Gallo SL; Department of Nuclear Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA., Zoberi JE; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA., Lee YC; Department of Radiation Oncology, Miami Cancer Institute, Baptist Health, Miami, Florida, USA.; Department of Radiation Oncology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
Jazyk: angličtina
Zdroj: Journal of applied clinical medical physics [J Appl Clin Med Phys] 2024 Nov 13, pp. e14550. Date of Electronic Publication: 2024 Nov 13.
DOI: 10.1002/acm2.14550
Abstrakt: Purpose: This study investigates potential failure modes and conducts failure mode and effects analysis (FMEA) and fault tree analysis (FTA) on the administration of 177 Lu $^{177}{\rm Lu}$ DOTATATE (LUTATHERA) and 177 Lu $^{177}{\rm Lu}$ PSMA-617 (PLUVICTO). The quality management (QM) process in radiopharmaceutical therapies (RPTs) requires collaboration between nuclear medicine (NM) and radiation oncology (RO) departments. As part of a multi-institutional study, we surveyed various departments to identify and analyze failure modes, leading to a proposed comprehensive QM program. RPT teams in RO or NM clinics can benefit from this study by continually improving their practice.
Methods: We reviewed the literature to investigate the administration of Pluvicto and Lutathera, focusing on prospective procedural failures and potential failure modes (PFMs) and their outcomes. We distributed an FMEA survey to multiple experienced centers in 177 Lu $^{177}{\rm Lu}$ -based RPTs and calculated risk priority number (RPN) for various PFM. We conducted an FTA using this information to pinpoint the root causes of potential failures.
Results: The findings from the literature review and survey responses on the prospective study have identified several critical areas at risk of failure. These areas include non-optimized treatment delivery, inadequate patient monitoring, and lack of safety training, leading to radiation contamination from the dose excreted by the patients after treatment administration. A segmented FTA was created based on the FMEA results, focusing on radiation contamination with a high RPN value.
Conclusion: By identifying the root causes of failures and proposing targeted improvements to the existing QM measures, this analysis enhances safety in treatment delivery of 177 Lu $^{177}{\rm Lu}$ -based RPTs. Given the limited number of prospective risk analysis studies in RPTs, our research addresses the necessity for more such studies and recommends methods to apply this study to other RPTs.
(© 2024 The Author(s). Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.)
Databáze: MEDLINE
Externí odkaz: